-
公开(公告)号：WO2011159758A4
公开(公告)日：2012-03-08
申请号：PCT/US2011040439
申请日：2011-06-15
Applicant: MEDGENICS MEDICAL ISRAEL LTD , PEARLMAN ANDREW L , STERN BARUCH S
Inventor： PEARLMAN ANDREW L , STERN BARUCH S
CPC classification number: C07K14/505 , A61K31/70 , A61K38/00 , A61K38/1816 , A61K38/212 , A61K47/6901 , A61K48/0075 , C12N7/00 , C12N15/86 , C12N2710/10343
Abstract: Disclosed are long-lasting erythropoietin therapeutic formulations and the methods of use the formulations. The formulation comprises a genetically modified micro-organ that comprises a vector which comprises a nucleic acid sequence operably linked to one or more regulatory sequences, wherein the nucleic acid sequence encodes erythropoietin. Administration of the formulation to a subject in need at a therapeutic dosage increases and maintains hemoglobin levels for at least one month.
Abstract translation: 公开了持久的促红细胞生成素治疗制剂和使用制剂的方法。 该制剂包含经遗传修饰的微器官，其包含载体，其载体可操作地连接至一个或多个调节序列，其中所述核酸序列编码促红细胞生成素。 以治疗剂量将配方给予需要的受试者增加并维持血红蛋白水平至少一个月。
-
2.发明申请CARTILAGE PARTICLE TISSUE MIXTURES OPTIONALLY COMBINED WITH A CANCELLOUS CONSTRUCT 审中-公开软骨颗粒组织混合物可选地与一种颊部构造组合
公开(公告)号：WO2010083051A9
公开(公告)日：2010-10-28
申请号：PCT/US2010000108
申请日：2010-01-14
Applicant: PROCHON BIOTECH LTD , MUSCULOSKELETAL TRANSPLANT , YAYON AVNER , TRUNCALE KATHERINE G , BARKAY-OLAMI HILLA , CALLAHAN ALEX B , GERTZMAN ARTHUR A , HUANG YEN-CHEN , JACOBS MORRIS L , MUNSON JOHN C , SEMLER ERIC J , SHIKHANOVICH ROMAN , STERN BARUCH , SUNWOO MOON HAE , TOMFORD WILLIAM W , YANNARIELLO-BROWN JUDITH I
Inventor： YAYON AVNER , TRUNCALE KATHERINE G , BARKAY-OLAMI HILLA , CALLAHAN ALEX B , GERTZMAN ARTHUR A , HUANG YEN-CHEN , JACOBS MORRIS L , MUNSON JOHN C , SEMLER ERIC J , SHIKHANOVICH ROMAN , STERN BARUCH , SUNWOO MOON HAE , TOMFORD WILLIAM W , YANNARIELLO-BROWN JUDITH I
CPC classification number: A61K9/19 , A61K35/32 , A61K38/1825 , A61L27/3612 , A61L27/3654 , A61L27/54 , A61L2300/414 , A61L2300/602
Abstract: Mixtures, such as gels or pastes, comprising freeze-milled cartilage particles and exogenous growth factors are used for repairing chondral defects. Such mixtures may be applied to constructs comprising cancellous bone for implantation at the defect site. Suitable growth factors include variants of FGF-2, particularly variants that include a sole amino acid substitution for asparagine at amino acid 111 of the ß8-ß9 loop of the FGF-2 peptide. Such FGF-2 variants are released slowly and continuously at a constant rate from cartilage pastes. In other embodiments, the amino acid substituted for asparigine is glycine. Other variants that may be used include FGF-9 variants having truncated chains and a sole amino acid substitution in the ß8-ß9 loop of the FGF-9 peptide either for tryptophan at amino acid 144 or for asparagine at amino acid 143.
Abstract translation: 包含冷冻研磨的软骨颗粒和外源生长因子的混合物如凝胶或糊剂用于修复软骨缺陷。 这样的混合物可以应用于包含松质骨的构建体以植入缺损部位。 合适的生长因子包括FGF-2的变体，特别是在FGF-2肽的β8-β9环的氨基酸111处包含天冬酰胺的单一氨基酸取代的变体。 这种FGF-2变体从软骨膏以恒定速率缓慢和连续释放。 在其他实施方案中，取代天冬氨酸的氨基酸是甘氨酸。 可以使用的其他变体包括在FGF-9肽的β8-β9环中具有截短的链和唯一的氨基酸取代的FGF-9变体，其在第144位的氨基酸为色氨酸或第143位的氨基酸为天冬酰胺。
-
公开(公告)号：WO2011159758A2
公开(公告)日：2011-12-22
申请号：PCT/US2011/040439
申请日：2011-06-15
Applicant: MEDGENICS MEDICAL ISRAEL LTD. , PEARLMAN, Andrew, L. , STERN, Baruch, S.
Inventor： PEARLMAN, Andrew, L. , STERN, Baruch, S.
CPC classification number: C07K14/505 , A61K31/70 , A61K38/00 , A61K38/1816 , A61K38/212 , A61K47/6901 , A61K48/0075 , C12N7/00 , C12N15/86 , C12N2710/10343
Abstract: The present invention is directed to long-lasting erythropoietin therapeutic formulations and their methods of use wherein the formulation comprises a genetically modified micro-organ that comprises a vector which comprises a nucleic acid sequence operably linked to one or more regulatory sequences, wherein the nucleic acid sequence encodes erythropoietin.
Abstract translation: 本发明涉及持久促红细胞生成素治疗剂及其使用方法，其中所述制剂包含经遗传修饰的微器官，其包含载体，所述载体包含可操作地连接至一个或多个调节序列的核酸序列，其中所述核酸 序列编码促红细胞生成素。
-
Patent Agency Ranking4.发明申请DERMAL MICRO ORGANS, METHODS AND APPARATUSES FOR PRODUCING AND USING THE SAME 审中-公开DERMAL MICRO ORGANS，METHODS AND APPARATUSES FOR PRODUCTION ANDEASING THE SAME
公开(公告)号：WO2004099363A3
公开(公告)日：2005-06-02
申请号：PCT/US2004013194
申请日：2004-04-29
Applicant: MEDGENICS INC , BELLOMO STEPHEN F , LIPPIN ITZHAK , PIVA GUILLERMO ALBERTO , ROSENBERG LIOR , BUKHMAN MORDECHAY , STERN BARUCH S , SHALHEVET DAVID , SHAVITT MENACHEM D , PEARLMAN ANDREW L
Inventor： BELLOMO STEPHEN F , LIPPIN ITZHAK , PIVA GUILLERMO ALBERTO , ROSENBERG LIOR , BUKHMAN MORDECHAY , STERN BARUCH S , SHALHEVET DAVID , SHAVITT MENACHEM D , PEARLMAN ANDREW L
CPC classification number: A61B17/3468 , A61B10/0275 , A61B17/32053 , A61B17/322 , A61B2017/0023 , A61B2017/00969 , A61B2017/2808 , A61B2017/320052 , A61B2017/320064 , A61B2017/3225 , A61B2217/005 , A61F2/105 , A61K35/36 , A61K38/1816 , A61K38/193 , A61K38/2066 , A61K38/215 , A61K38/27 , A61K38/28 , A61M5/425 , C12N5/0698 , C12N2502/094 , C12N2502/1323 , C12N2510/00 , Y10T83/929
Abstract: Embodiments of the present invention provide Dermal Micro Organs (DMOs), methods and apparatuses for producing the same. Some embodiments of the invention provide a DMO including a plurality of dermal components, which substantially retain the micro-architecture and three dimensional structure of the dermal tissue from which they are derived, having dimensions selected so as to allow passive diffusion of adequate nutrients and gases to cells of the DMO and diffusion of cellular waste out of the cells so as to minimize cellular toxicity and concomitant death due to insufficient nutrition and accumulation of waste in the DMO. Some embodiments of the invention provide methods and apparatuses for harvesting the DMO. An apparatus for harvesting the DMO may include, according to some exemplary embodiments, a support configuration to support a skin-related tissue structure from which the DMO is to be harvested, and a cutting tool able to separate the DMO from the skin-related tissue structure. Other embodiments are described and claimed.
Abstract translation: 本发明的实施方案提供了皮肤微器官（DMO），其制造方法和装置。 本发明的一些实施方案提供了包含多个皮肤成分的DMO，其基本上保留了衍生自它们的真皮组织的微结构和三维结构，其尺寸被选择为允许适当营养物和气体的被动扩散 到DMO的细胞并将细胞废物扩散出细胞，以便最小化细胞毒性和由于DMO中的营养不足和废物积聚引起的伴随死亡。 本发明的一些实施例提供了用于收获DMO的方法和装置。 根据一些示例性实施例，用于收获DMO的装置可以包括用于支撑要从其中收获DMO的与皮肤相关的组织结构的支撑构型，以及能够将DMO与皮肤相关组织分离的切割工具 结构体。 描述和要求保护其他实施例。
-
5.发明申请CARTILAGE PARTICLE TISSUE MIXTURES OPTIONALLY COMBINED WITH A CANCELLOUS CONSTRUCT 审中-公开卡特彼勒组合混合物与CANCELLOUS CONSTRUCT选择性组合
公开(公告)号：WO2010083051A2
公开(公告)日：2010-07-22
申请号：PCT/US2010/000108
申请日：2010-01-14
Applicant: PROCHON BIOTECH, LTD. , MUSCULOSKELETAL TRANSPLANT FOUNDATION , YAYON, Avner , TRUNCALE, Katherine, G. , BARKAY-OLAMI, Hilla , CALLAHAN, Alex, B. , GERTZMAN, Arthur, A. , HUANG, Yen-chen , JACOBS, Morris, L. , MUNSON, John, C. , SEMLER, Eric, J. , SHIKHANOVICH, Roman , STERN, Baruch , SUNWOO, Moon, Hae , TOMFORD, William, W. , YANNARIELLO-BROWN, Judith, I.
Inventor： YAYON, Avner , TRUNCALE, Katherine, G. , BARKAY-OLAMI, Hilla , CALLAHAN, Alex, B. , GERTZMAN, Arthur, A. , HUANG, Yen-chen , JACOBS, Morris, L. , MUNSON, John, C. , SEMLER, Eric, J. , SHIKHANOVICH, Roman , STERN, Baruch , SUNWOO, Moon, Hae , TOMFORD, William, W. , YANNARIELLO-BROWN, Judith, I.
IPC: A61K38/18
CPC classification number: A61K9/19 , A61K35/32 , A61K38/1825 , A61L27/3612 , A61L27/3654 , A61L27/54 , A61L2300/414 , A61L2300/602
Abstract: Mixtures, such as gels or pastes, comprising freeze-milled cartilage particles and exogenous growth factors are used for repairing chondral defects. Such mixtures may be applied to constructs comprising cancellous bone for implantation at the defect site. Suitable growth factors include variants of FGF-2, particularly variants that include a sole amino acid substitution for asparagine at amino acid 111 of the β8-β9 loop of the FGF-2 peptide. Such FGF-2 variants are released slowly and continuously at a constant rate from cartilage pastes. In other embodiments, the amino acid substituted for asparigine is glycine. Other variants that may be used include FGF-9 variants having truncated chains and a sole amino acid substitution in the β8-β9 loop of the FGF-9 peptide either for tryptophan at amino acid 144 or for asparagine at amino acid 143.
Abstract translation: 使用包含冷冻研磨的软骨颗粒和外源生长因子的混合物，例如凝胶或糊剂来修复软骨缺陷。 可以将这样的混合物施用于包含用于在缺损部位植入的松质骨的构建体。 合适的生长因子包括FGF-2的变体，特别是在FGF-2肽的β8-β9环的氨基酸111处包括天冬酰胺的唯一氨基酸取代的变体。 这样的FGF-2变体以软骨糊剂的恒定速率缓慢且连续地释放。 在其它实施方案中，取代天冬酰胺的氨基酸是甘氨酸。 可以使用的其它变体包括在FGF-9肽的β8-β9环中具有截短链的FGF-9变体和在氨基酸144处的色氨酸或在氨基酸143处的天冬酰胺的唯一氨基酸取代。
-
公开(公告)号：WO2011159758A3
公开(公告)日：2012-02-09
申请号：PCT/US2011040439
申请日：2011-06-15
Applicant: MEDGENICS MEDICAL ISRAEL LTD , PEARLMAN ANDREW L , STERN BARUCH S
Inventor： PEARLMAN ANDREW L , STERN BARUCH S
CPC classification number: C07K14/505 , A61K31/70 , A61K38/00 , A61K38/1816 , A61K38/212 , A61K47/6901 , A61K48/0075 , C12N7/00 , C12N15/86 , C12N2710/10343
Abstract: Disclosed are long-lasting erythropoietin therapeutic formulations and the methods of use the formulations. The formulation comprises a genetically modified micro-organ that comprises a vector which comprises a nucleic acid sequence operably linked to one or more regulatory sequences, wherein the nucleic acid sequence encodes erythropoietin. Administration of the formulation to a subject in need at a therapeutic dosage increases and maintains hemoglobin levels for at least one month.
Abstract translation: 公开了长效促红细胞生成素治疗制剂和制剂的使用方法。 该制剂包含经遗传修饰的微器官，其包含载体，该载体包含与一个或多个调控序列可操作地连接的核酸序列，其中该核酸序列编码促红细胞生成素。 将制剂以治疗剂量给予有需要的受试者增加并维持血红蛋白水平至少一个月。
-
公开(公告)号：WO2010083051A3
公开(公告)日：2010-09-23
申请号：PCT/US2010000108
申请日：2010-01-14
Applicant: PROCHON BIOTECH LTD , MUSCULOSKELETAL TRANSPLANT , YAYON AVNER , TRUNCALE KATHERINE G , BARKAY-OLAMI HILLA , CALLAHAN ALEX B , GERTZMAN ARTHUR A , HUANG YEN-CHEN , JACOBS MORRIS L , MUNSON JOHN C , SEMLER ERIC J , SHIKHANOVICH ROMAN , STERN BARUCH , SUNWOO MOON HAE , TOMFORD WILLIAM W , YANNARIELLO-BROWN JUDITH I
Inventor： YAYON AVNER , TRUNCALE KATHERINE G , BARKAY-OLAMI HILLA , CALLAHAN ALEX B , GERTZMAN ARTHUR A , HUANG YEN-CHEN , JACOBS MORRIS L , MUNSON JOHN C , SEMLER ERIC J , SHIKHANOVICH ROMAN , STERN BARUCH , SUNWOO MOON HAE , TOMFORD WILLIAM W , YANNARIELLO-BROWN JUDITH I
CPC classification number: A61K9/19 , A61K35/32 , A61K38/1825 , A61L27/3612 , A61L27/3654 , A61L27/54 , A61L2300/414 , A61L2300/602
Abstract: Mixtures, such as gels or pastes, comprising freeze-milled cartilage particles and exogenous growth factors are used for repairing chondral defects. Such mixtures may be applied to constructs comprising cancellous bone for implantation at the defect site. Suitable growth factors include variants of FGF-2, particularly variants that include a sole amino acid substitution for asparagine at amino acid 111 of the ß8-ß9 loop of the FGF-2 peptide. Such FGF-2 variants are released slowly and continuously at a constant rate from cartilage pastes. In other embodiments, the amino acid substituted for asparigine is glycine. Other variants that may be used include FGF-9 variants having truncated chains and a sole amino acid substitution in the ß8-ß9 loop of the FGF-9 peptide either for tryptophan at amino acid 144 or for asparagine at amino acid 143.
-
8.发明申请DERMAL MICRO ORGANS, METHODS AND APPARATUSES FOR PRODUCING AND USING THE SAME 审中-公开DERMAL MICRO ORGANS，METHODS AND APPARATUSES FOR PRODUCTION ANDEASING THE SAME
公开(公告)号：WO2004099363A2
公开(公告)日：2004-11-18
申请号：PCT/US2004/013194
申请日：2004-04-29
Applicant: MEDGENICS INC. , BELLOMO, Stephen, F. , LIPPIN, Itzhak , PIVA, Guillermo, Alberto , ROSENBERG, Lior , BUKHMAN, Mordechay , STERN, Baruch, S. , SHALHEVET, David , SHAVITT, Menachem, D. , PEARLMAN, Andrew, L.
Inventor： BELLOMO, Stephen, F. , LIPPIN, Itzhak , PIVA, Guillermo, Alberto , ROSENBERG, Lior , BUKHMAN, Mordechay , STERN, Baruch, S. , SHALHEVET, David , SHAVITT, Menachem, D. , PEARLMAN, Andrew, L.
IPC: C12M
CPC classification number: A61B17/3468 , A61B10/0275 , A61B17/32053 , A61B17/322 , A61B2017/0023 , A61B2017/00969 , A61B2017/2808 , A61B2017/320052 , A61B2017/320064 , A61B2017/3225 , A61B2217/005 , A61F2/105 , A61K35/36 , A61K38/1816 , A61K38/193 , A61K38/2066 , A61K38/215 , A61K38/27 , A61K38/28 , A61M5/425 , C12N5/0698 , C12N2502/094 , C12N2502/1323 , C12N2510/00 , Y10T83/929
Abstract: Embodiments of the present invention provide Dermal Micro Organs (DMOs), methods and apparatuses for producing the same. Some embodiments of the invention provide a DMO including a plurality of dermal components, which substantially retain the micro-architecture and three dimensional structure of the dermal tissue from which they are derived, having dimensions selected so as to allow passive diffusion of adequate nutrients and gases to cells of the DMO and diffusion of cellular waste out of the cells so as to minimize cellular toxicity and concomitant death due to insufficient nutrition and accumulation of waste in the DMO. Some embodiments of the invention provide methods and apparatuses for harvesting the DMO. An apparatus for harvesting the DMO may include, according to some exemplary embodiments, a support configuration to support a skin-related tissue structure from which the DMO is to be harvested, and a cutting tool able to separate the DMO from the skin-related tissue structure. Other embodiments are described and claimed.
Abstract translation: 本发明的实施方案提供了皮肤微器官（DMO），其制造方法和装置。 本发明的一些实施方案提供了包含多个皮肤成分的DMO，其基本上保留了衍生自它们的真皮组织的微结构和三维结构，其尺寸被选择为允许适当营养物和气体的被动扩散 到DMO的细胞并将细胞废物扩散出细胞，以便最小化细胞毒性和由于DMO中的营养不足和废物积聚引起的伴随死亡。 本发明的一些实施例提供了用于收获DMO的方法和装置。 根据一些示例性实施例，用于收获DMO的装置可以包括用于支撑要从其中收获DMO的与皮肤相关的组织结构的支撑构型，以及能够将DMO与皮肤相关组织分离的切割工具 结构体。 描述和要求保护其他实施例。
-
-
-
-
-
-
-
Search Results
8
records
(took 0.06 seconds)
